SHENZHEN, CHINA, April 27, 2026 (GLOBE NEWSWIRE) — China Medical System Holdings Restricted (“CMS” or the “Group”) is happy to announce that, the Group by its wholly-owned subsidiary entered into an unique commercialization and provide settlement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) not too long ago. In accordance with the Settlement, the Group has obtained an unique proper to commercialize the merchandise within the Folks’s Republic of China (for the aim of this Settlement, excluding the Hong Kong Particular Administrative Area, the Macau Particular Administrative Area and Taiwan area). Pharmacosmos A/S will proceed to fabricate and provide the merchandise. The cooperation time period shall be fifteen years from the efficient date stipulated within the Settlement, which can be prolonged upon mutual settlement between the events previous to expiry.
The 2 intravenous iron therapies underneath this cooperation are each originator merchandise which were permitted for advertising and marketing in China and included within the China’s Nationwide Reimbursement Drug Listing (NRDL). Amongst them, Monofer® is an unique drug and the primary third-generation intravenous iron remedy permitted for advertising and marketing in China. It options an modern and extra steady matrix-like nanostructure and gives a superior security profile[1]. Its single-dose full iron replenishment considerably reduces the variety of infusions, permits quicker enchancment in hemoglobin ranges and enhances medical comfort. One other product, Cosmofer®, is at the moment the one intravenous iron remedy included in Class A of the NRDL and likewise the one one included within the Nationwide Important Medicines Listing (NEML). With a few years of collected medical use, its efficacy and security have been supported by collected medical expertise and printed information.
The above two merchandise will kind a complete intravenous iron product portfolio overlaying all channels and therapy situations, which might help assembly the medical wants of various ranges of healthcare establishments and various kinds of iron deficiency anemia (IDA) sufferers, offering extra diversified, secure and efficient therapy choices for sufferers. Sufferers with iron deficiency (ID) and IDA are broadly distributed throughout a number of medical departments, together with gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, that are all key specialty areas of the Group. The addition of the 2 merchandise will generate environment friendly synergies with the Group’s current marketed merchandise in skilled assets and tutorial promotion community, additional strengthening the Group’s general competitiveness within the discipline of anemia therapy, and is anticipated to have a constructive impression on the Group’s efficiency.
Extra details about Monofer®Monofer® was permitted on 30 January 2021 for the therapy of iron deficiency in sufferers the place oral iron preparations are ineffective, can’t be used, or the place there’s a medical want for speedy iron supplementation. In 2023, Monofer® was included within the NRDL as a Class B reimbursable drug. Monofer® consists of nanoparticles with a steady, matrix-like construction composed of interchanging layers of iron atoms and brief, linear isomaltose carbohydrates. This construction permits managed iron launch with low ranges of labile iron, contributing to a beneficial security profile, together with a low danger of hypersensitivity reactions and hypophosphatemia. Monofer® might be administered as a high-dose infusion of 1,000 mg or extra in a single go to, whereas older therapies equivalent to iron sucrose usually require repeated administrations of 100 to 200 mg. This permits full iron repletion in a single therapy, decreasing the necessity for a number of infusions, decreasing the burden on sufferers and healthcare methods, and rising infusion capability. On the identical time, the low danger of hypophosphatemia helps keep away from issues equivalent to fractures and helps restoration from fatigue, a key symptom of iron deficiency anaemia.
Extra details about Cosmofer®Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was permitted for advertising and marketing in Mainland China in 2003 and is indicated for sufferers with iron deficiency who can’t take oral iron preparations (equivalent to those that are illiberal to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® additionally permits single-dose high-dose iron repletion. With a few years of collected medical use, its efficacy and security have been supported by collected medical expertise and printed information. Its twin standing as a Class A NRDL-listed product and NEML helps its core position in iron supplementation in main healthcare settings.
More Read
About Iron Deficiency and Iron Deficiency AnemiaID and IDA are world well being points that generally have an effect on youngsters, premenopausal girls (significantly pregnant girls) and the aged. These circumstances might impair the perform of a number of organ methods, resulting in a collection of well being issues equivalent to progress retardation, behavioral issues, cognitive impairment, decreased bodily capability, and peri-natal and peri-operative issues. In addition they considerably have an effect on the prognosis of power illnesses equivalent to gastrointestinal illnesses, power kidney illness, coronary heart failure and tumors[2]. Greater than 1 billion individuals stay with iron deficiency anaemia[3], making it one of many main contributors to the worldwide burden of illness[4]. Information from the Fourth Nationwide Vitamin Survey in China point out that the prevalence of IDA amongst Chinese language residents is 20.1%[5]. Nonetheless, each sufferers and healthcare professionals have inadequate consciousness of the illness. Lower than 20% of sufferers with delicate anemia obtain analysis and therapy, whereas solely about 50% of sufferers with extreme anemia obtain acceptable analysis and therapy[2]. This means vital underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the usual therapy for ID/IDA and contains oral iron remedy and intravenous iron remedy. Intravenous iron remedy is a crucial choice for sufferers who can’t tolerate oral iron, have insufficient response to oral remedy, require speedy iron repletion, or desire full iron supplementation inside one to 2 administrations[1,2,6]. Nonetheless, as a result of inadequate consciousness of IDA, affected person adherence points, hospitalization constraints, infusion comfort, and security issues relating to intravenous iron therapies, the medical use of intravenous iron in China stays comparatively conservative. A Chinese language real-world examine reveals that the typical complete dose of iron sucrose utilized in IDA sufferers was roughly 511 mg, which was considerably decrease than the goal dose of 1,000 mg[2]. There may be due to this fact a big medical want for intravenous iron therapies that provide excessive security, sturdy demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® collectively set up a complete intravenous iron product portfolio overlaying a number of therapy situations, offering tiered therapy choices for sufferers with iron deficiency anemia.
About Pharmacosmos A/SPharmacosmos A/S is a world chief in carbohydrate chemistry and modern remedies for iron deficiency and iron deficiency anemia. Leveraging its deep experience in carbohydrate chemistry and cell cycle biology, the corporate is dedicated to creating modern therapies to handle unmet affected person wants, with a selected concentrate on iron metabolism and hematology-related illnesses. Pharmacosmos A/S was based in 1965 and is headquartered in Denmark, and employs greater than 700 specialists from the UK, Eire, the Nordic nations, Germany, america, Canada and China. With glorious product high quality and powerful medical worth, its core iron remedy merchandise have been permitted and broadly utilized in a number of nations and areas worldwide, establishing sturdy technological capabilities and a strong market popularity.
About CMS
More Read
CMS is a platform firm linking pharmaceutical innovation and commercialization with sturdy product lifecycle administration functionality, devoted to offering aggressive services to satisfy unmet medical wants.
CMS focuses on the worldwide first-in-class (FIC) and best-in-class (BIC) modern merchandise, and effectively promotes the medical analysis, improvement and commercialization of modern merchandise, enabling the continual transformation of scientific analysis into medical practices to learn sufferers.
CMS deeply engages in a number of specialty therapeutic fields, and has developed confirmed commercialization capabilities, in depth networks and skilled assets, leading to main tutorial and market positions for its main marketed merchandise. CMS continues to advertise the in-depth improvement in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/pores and skin well being companies, bringing economies of scale in specialty fields. Amongst them, the pores and skin well being enterprise (Dermavon) has develop into a number one enterprise in its discipline, and is proposed to be listed independently on the SEHK. In the meantime, CMS constantly promotes the operation and improvement of its built-in R&D, manufacturing and commercialization chain in Southeast Asia and the Center East, capturing progress alternatives in rising markets to help the high-quality and sustainable improvement of the Group.
Reference:
Chinese language Pharmacological Society Skilled Committee of Drug‑induced Illnesses, Guangdong Pharmaceutical Affiliation. Skilled consensus of medical utility and pharmaceutical look after intravenous iron brokers (2024) [J]. Adversarial Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃00070Liao Minjing, Zhang Liansheng. Standardized analysis and therapy of iron deficiency and iron‑deficiency anemia [J]. Chinese language Journal of Inner Drugs, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.International Burden of Illness Collaborative Community. International Burden of Illness Examine 2019 (GBD 2019) Outcomes. Seattle, United States: Institute for Well being Metrics and Analysis (IHME); 2020. Out there from http://ghdx.healthdata.org/gbd-results-tool.Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.Li Lijuan, Zhang Liansheng. Concerns on the standardized analysis and therapy of iron‑deficiency anemia [J]. Nationwide Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.Purple Blood Cell Illness (Anemia) Group, Chinese language Society of Hematology, Chinese language Medical Affiliation. Multidisciplinary skilled consensus on the analysis, therapy and prevention of iron deficiency and iron deficiency anemia (2022 version) [J]. Nationwide Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.
CMS Disclaimer and Ahead-Trying Statements
More Read
This press launch is just not supposed to advertise any merchandise to you and isn’t for promoting functions. This press launch doesn’t suggest any medicine, medical units and/or indications. If you wish to know extra in regards to the analysis and therapy of particular illnesses, please observe the opinions or steerage of your physician or different medical and well being professionals. Any treatment-related selections made by healthcare professionals needs to be based mostly on the affected person’s particular circumstances and in accordance with the drug package deal insert.
This press launch which has been ready by CMS doesn’t represent any supply or invitation to buy or subscribe for any securities, and shall not kind the idea for or be relied on in reference to any contract or binding dedication in any respect. This press launch has been ready by CMS based mostly on info and information which it considers dependable, however CMS makes no illustration or guarantee, categorical or implied, in any respect, and no reliance shall be positioned on, the reality, accuracy, completeness, equity and reasonableness of the contents of this press launch. Sure issues mentioned on this press launch might include statements relating to the Group’s market alternative and enterprise prospects which are individually and collectively forward-looking statements. Such forward-looking statements usually are not ensures of future efficiency and are topic to identified and unknown dangers, uncertainties and assumptions which are troublesome to foretell. Any forward-looking statements and projections made by third events included on this press launch usually are not adopted by the Group and the Firm is just not chargeable for such third-party statements and projections.
Media Contact
Model: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Web site: https://net.cms.internet.cn/en/residence/
